MIT Technology Review is a technology publication founded by the Massachusetts Institute of Technology. Its AI coverage combines reporting and analysis on research, companies, policy, products, and the wider consequences of artificial intelligence.
A new approach in AI-driven drug discovery seeks to 'close the data loop,' addressing inefficiencies in the traditional pharmaceutical development process. Integrating AI with experimental feedback is highlighted as a way to potentially accelerate timelines and reduce costs, which have historically doubled every nine years according to Eroom’s Law. This shift is seen as a response to increasing market pressures for faster and more cost-effective drug development.
Why it matters: Improving the efficiency of drug discovery with AI could significantly impact healthcare innovation and patient access to new treatments.
Infrastructure→Reported→MIT Technology Review / AI
Agentic AI offers the potential for software agents to execute business tasks end-to-end across people, workflows, data, and systems. To support these agents, enterprise platforms need sufficient CPU capacity, resilient data access, policy-aware tool use, observability, and memory management.
Why it matters: Understanding the infrastructure requirements for agentic AI highlights the shift from simple chatbots to more autonomous business process execution.
Artificial intelligence is increasingly being used to assist scientists in designing new medicines, especially biologic therapies made from engineered proteins. By leveraging AI, researchers can more efficiently identify promising drug candidates, potentially reducing the time and cost associated with traditional drug development.
Why it matters: AI-driven drug design could accelerate the development of innovative treatments and improve patient outcomes.
Policy & Safety→Reported→MIT Technology Review / AI
OpenAI has developed GPT-Red, a large language model designed to act as a super-hacker sparring partner to improve the security of its other models. According to the company, training its latest flagship model, GPT-5.6, against GPT-Red resulted in its most robust release yet.
Why it matters: This approach uses one LLM to automatically red-team another, representing a novel method for improving AI model robustness and safety.
Anthropic has developed a technique called the Jacobian lens that provides the clearest view yet of how large language models like Claude process information internally. Their findings reveal a hidden conceptual space within the model, with insights ranging from the mundane to the unnerving.
Why it matters: This breakthrough offers unprecedented transparency into AI reasoning, which could improve the safety and interpretability of large language models.
Products & Agents→Reported→MIT Technology Review / AI
Anthropic has announced Claude Science, a new product aimed at supporting scientific research by autonomously performing meaningful tasks from high-level instructions. The announcement took place at an event attended by pharmaceutical executives, biotech founders, and researchers.
Why it matters: Claude Science represents Anthropic's move into automating scientific research, which could accelerate progress in areas such as drug development.